We use cookies to give you the best browsing experience, site traffic analysis, and advertisement management.
Harnessing the power
Therapeutic portfolio
Pure Biologics’ therapeutic portfolio includes new immunooncology therapies and non-systemic treatment of autoimmune, neurodegenerative and rare diseases. It is a total of a dozen projects, including five key projects in which we use antibody and aptamer technologies to develop molecules with therapeutic potential.
Contract research
Pure Biologics engages in commercial collaboration, offering contract research covering three main specialties – aptamers, antibodies and proteins. Our solutions combine a team of highly qualified scientists, the potential of our technology platforms and many years of operational experience.
Investors & media
Pure Biologics is the first entity in Poland to focus on development of completely new, not generic or biosimilar, biological drugs based on antibodies and therapeutic aptamers. This is a challenge that is currently a leading trend in the global pharmaceutical industry.